Baseline and Clinical Characteristics of Patients With Health Care–Associated Bacteremia of Urinary Origin Caused by Klebsiella pneumoniae Complex.
| . | Total (N = 96) . | Non-3GC/CR (n = 53) . | 3GC/CR (n = 43) . | P Value . |
|---|---|---|---|---|
| Age y | 71.1 (64.5–80.0) | 71.8 (65.0–81.0) | 70.3 (64.0–77.0) | .333 |
| Sex: female | 29 (30.2) | 19 (35.8) | 10 (23.3) | .264 |
| Charlson index | 6.4 (5.0–8.0) | 6.5 (5.0–8.0) | 6.3 (5.0–8.0) | .877 |
| Any underlying disease | 85 (88.5) | 48 (98.6) | 37 (86.0) | .534 |
| McCabe: II or III | 33 (34.4) | 16 (30.2) | 17 (39.5) | .391 |
| Diabetes mellitus | 37 (38.5) | 17 (32.1) | 20 (46.5) | .206 |
| Chronic pulmonary disease | 10 (10.4) | 6 (11.3) | 4 (9.3) | >.99 |
| Chronic heart disease | 31 (32.3) | 19 (35.8) | 12 (27.9) | .511 |
| Chronic kidney disease | 34 (35.4) | 19 (35.8) | 15 (34.9) | >.99 |
| Chronic liver disease | 5 (5.2) | 2 (3.8) | 3 (7.0) | .654 |
| Vascular/degenerative brain disease | 17 (17.7) | 6 (11.3) | 11 (25.6) | .105 |
| Malignant disease | 41 (42.7) | 25 (47.2) | 16 (37.2) | .408 |
| Immunosuppressive therapy | 28 (29.2) | 16 (30.2) | 12 (27.9) | .826 |
| Recurrent UTI: >2 episodes/y | 22 (23.9) | 8 (15.7) | 14 (33.3) | .054 |
| Indwelling urinary devicesa | 17 (17.7) | 12 (22.6) | 5 (11.6) | .188 |
| Community-onset HCA acquisition | 37 (38.5) | 23 (43.4) | 14 (32.6) | .300 |
| Prior antibiotic use: 90 d | 69 (71.9) | 32 (60.4) | 37 (86.0) | .006 |
| Pitt score: >2 | 32 (33.3) | 18 (34.0) | 14 (32.6) | >.99 |
| Sepsis or shock | 14 (15.2) | 8 (15.7) | 6 (14.6) | >.99 |
| Inadequate empirical treatment | 12 (12.5) | 2 (3.8) | 10 (23.3) | .005 |
| Antimicrobial therapy duration | 15.9 (12.0–17.0) | 15.9 (12.0–18.0) | 15.8 (12.0–17.0) | .593 |
| . | Total (N = 96) . | Non-3GC/CR (n = 53) . | 3GC/CR (n = 43) . | P Value . |
|---|---|---|---|---|
| Age y | 71.1 (64.5–80.0) | 71.8 (65.0–81.0) | 70.3 (64.0–77.0) | .333 |
| Sex: female | 29 (30.2) | 19 (35.8) | 10 (23.3) | .264 |
| Charlson index | 6.4 (5.0–8.0) | 6.5 (5.0–8.0) | 6.3 (5.0–8.0) | .877 |
| Any underlying disease | 85 (88.5) | 48 (98.6) | 37 (86.0) | .534 |
| McCabe: II or III | 33 (34.4) | 16 (30.2) | 17 (39.5) | .391 |
| Diabetes mellitus | 37 (38.5) | 17 (32.1) | 20 (46.5) | .206 |
| Chronic pulmonary disease | 10 (10.4) | 6 (11.3) | 4 (9.3) | >.99 |
| Chronic heart disease | 31 (32.3) | 19 (35.8) | 12 (27.9) | .511 |
| Chronic kidney disease | 34 (35.4) | 19 (35.8) | 15 (34.9) | >.99 |
| Chronic liver disease | 5 (5.2) | 2 (3.8) | 3 (7.0) | .654 |
| Vascular/degenerative brain disease | 17 (17.7) | 6 (11.3) | 11 (25.6) | .105 |
| Malignant disease | 41 (42.7) | 25 (47.2) | 16 (37.2) | .408 |
| Immunosuppressive therapy | 28 (29.2) | 16 (30.2) | 12 (27.9) | .826 |
| Recurrent UTI: >2 episodes/y | 22 (23.9) | 8 (15.7) | 14 (33.3) | .054 |
| Indwelling urinary devicesa | 17 (17.7) | 12 (22.6) | 5 (11.6) | .188 |
| Community-onset HCA acquisition | 37 (38.5) | 23 (43.4) | 14 (32.6) | .300 |
| Prior antibiotic use: 90 d | 69 (71.9) | 32 (60.4) | 37 (86.0) | .006 |
| Pitt score: >2 | 32 (33.3) | 18 (34.0) | 14 (32.6) | >.99 |
| Sepsis or shock | 14 (15.2) | 8 (15.7) | 6 (14.6) | >.99 |
| Inadequate empirical treatment | 12 (12.5) | 2 (3.8) | 10 (23.3) | .005 |
| Antimicrobial therapy duration | 15.9 (12.0–17.0) | 15.9 (12.0–18.0) | 15.8 (12.0–17.0) | .593 |
Data are presented as No. (%) or median (IQR). Statistically significant values are in bold.
Abbreviations: HCA, health care associated; non-3GC/CR, not third-generation cephalosporin or carbapenem resistant; UTI, urinary tract infection.
aIndwelling urinary device or an invasive urinary procedure within the last 30 days.
Baseline and Clinical Characteristics of Patients With Health Care–Associated Bacteremia of Urinary Origin Caused by Klebsiella pneumoniae Complex.
| . | Total (N = 96) . | Non-3GC/CR (n = 53) . | 3GC/CR (n = 43) . | P Value . |
|---|---|---|---|---|
| Age y | 71.1 (64.5–80.0) | 71.8 (65.0–81.0) | 70.3 (64.0–77.0) | .333 |
| Sex: female | 29 (30.2) | 19 (35.8) | 10 (23.3) | .264 |
| Charlson index | 6.4 (5.0–8.0) | 6.5 (5.0–8.0) | 6.3 (5.0–8.0) | .877 |
| Any underlying disease | 85 (88.5) | 48 (98.6) | 37 (86.0) | .534 |
| McCabe: II or III | 33 (34.4) | 16 (30.2) | 17 (39.5) | .391 |
| Diabetes mellitus | 37 (38.5) | 17 (32.1) | 20 (46.5) | .206 |
| Chronic pulmonary disease | 10 (10.4) | 6 (11.3) | 4 (9.3) | >.99 |
| Chronic heart disease | 31 (32.3) | 19 (35.8) | 12 (27.9) | .511 |
| Chronic kidney disease | 34 (35.4) | 19 (35.8) | 15 (34.9) | >.99 |
| Chronic liver disease | 5 (5.2) | 2 (3.8) | 3 (7.0) | .654 |
| Vascular/degenerative brain disease | 17 (17.7) | 6 (11.3) | 11 (25.6) | .105 |
| Malignant disease | 41 (42.7) | 25 (47.2) | 16 (37.2) | .408 |
| Immunosuppressive therapy | 28 (29.2) | 16 (30.2) | 12 (27.9) | .826 |
| Recurrent UTI: >2 episodes/y | 22 (23.9) | 8 (15.7) | 14 (33.3) | .054 |
| Indwelling urinary devicesa | 17 (17.7) | 12 (22.6) | 5 (11.6) | .188 |
| Community-onset HCA acquisition | 37 (38.5) | 23 (43.4) | 14 (32.6) | .300 |
| Prior antibiotic use: 90 d | 69 (71.9) | 32 (60.4) | 37 (86.0) | .006 |
| Pitt score: >2 | 32 (33.3) | 18 (34.0) | 14 (32.6) | >.99 |
| Sepsis or shock | 14 (15.2) | 8 (15.7) | 6 (14.6) | >.99 |
| Inadequate empirical treatment | 12 (12.5) | 2 (3.8) | 10 (23.3) | .005 |
| Antimicrobial therapy duration | 15.9 (12.0–17.0) | 15.9 (12.0–18.0) | 15.8 (12.0–17.0) | .593 |
| . | Total (N = 96) . | Non-3GC/CR (n = 53) . | 3GC/CR (n = 43) . | P Value . |
|---|---|---|---|---|
| Age y | 71.1 (64.5–80.0) | 71.8 (65.0–81.0) | 70.3 (64.0–77.0) | .333 |
| Sex: female | 29 (30.2) | 19 (35.8) | 10 (23.3) | .264 |
| Charlson index | 6.4 (5.0–8.0) | 6.5 (5.0–8.0) | 6.3 (5.0–8.0) | .877 |
| Any underlying disease | 85 (88.5) | 48 (98.6) | 37 (86.0) | .534 |
| McCabe: II or III | 33 (34.4) | 16 (30.2) | 17 (39.5) | .391 |
| Diabetes mellitus | 37 (38.5) | 17 (32.1) | 20 (46.5) | .206 |
| Chronic pulmonary disease | 10 (10.4) | 6 (11.3) | 4 (9.3) | >.99 |
| Chronic heart disease | 31 (32.3) | 19 (35.8) | 12 (27.9) | .511 |
| Chronic kidney disease | 34 (35.4) | 19 (35.8) | 15 (34.9) | >.99 |
| Chronic liver disease | 5 (5.2) | 2 (3.8) | 3 (7.0) | .654 |
| Vascular/degenerative brain disease | 17 (17.7) | 6 (11.3) | 11 (25.6) | .105 |
| Malignant disease | 41 (42.7) | 25 (47.2) | 16 (37.2) | .408 |
| Immunosuppressive therapy | 28 (29.2) | 16 (30.2) | 12 (27.9) | .826 |
| Recurrent UTI: >2 episodes/y | 22 (23.9) | 8 (15.7) | 14 (33.3) | .054 |
| Indwelling urinary devicesa | 17 (17.7) | 12 (22.6) | 5 (11.6) | .188 |
| Community-onset HCA acquisition | 37 (38.5) | 23 (43.4) | 14 (32.6) | .300 |
| Prior antibiotic use: 90 d | 69 (71.9) | 32 (60.4) | 37 (86.0) | .006 |
| Pitt score: >2 | 32 (33.3) | 18 (34.0) | 14 (32.6) | >.99 |
| Sepsis or shock | 14 (15.2) | 8 (15.7) | 6 (14.6) | >.99 |
| Inadequate empirical treatment | 12 (12.5) | 2 (3.8) | 10 (23.3) | .005 |
| Antimicrobial therapy duration | 15.9 (12.0–17.0) | 15.9 (12.0–18.0) | 15.8 (12.0–17.0) | .593 |
Data are presented as No. (%) or median (IQR). Statistically significant values are in bold.
Abbreviations: HCA, health care associated; non-3GC/CR, not third-generation cephalosporin or carbapenem resistant; UTI, urinary tract infection.
aIndwelling urinary device or an invasive urinary procedure within the last 30 days.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
